Browse the evidence

Semaglutide significantly reduces the risk of acute myocardial infarction and angina pectoris in patients with overweight or obesity, with greater efficacy observed in patients over 60 years and those treated for more than 52 weeks.

For patients with overweight or obesity, semaglutide (up to 2.4 mg) significantly lowers the risk of heart attacks and angina. This benefit is particularly pronounced in patients over 60 years old and those who maintain treatment for more than one year, suggesting that long-term adherence is key to maximizing cardiovascular protection.

GLP-1 receptor agonists (semaglutide) and dual GLP-1/GIP agonists (tirzepatide) significantly improve cardiovascular outcomes and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, though they carry a risk of lean mass loss.

If you have HFpEF and obesity, GLP-1/GIP medications like semaglutide or tirzepatide can significantly improve your heart health, symptoms, and quality of life. To counteract potential muscle loss, you must combine these medications with resistance training and high protein intake. Discuss these options with your cardiologist, as they are increasingly recognized as effective treatments for this specific heart condition.

Tirzepatide reduces liver fat content and visceral adipose tissue in patients with Type 2 Diabetes.

If you have Type 2 Diabetes and are concerned about liver health, tirzepatide not only helps control blood sugar and weight but also significantly reduces liver fat, which is beneficial for overall metabolic health.

Resmetirom (80-100 mg daily) significantly improves MASH resolution and fibrosis regression in patients with F2-F3 fibrosis compared to placebo.

If you have moderate-to-advanced liver scarring from MASH, resmetirom is the first approved drug to help reverse it. Take 80mg or 100mg daily. Expect possible mild stomach issues, but serious risks are low. This targets the root hormonal imbalance driving liver fat.

GLP-1 receptor agonists (e.g., Semaglutide) improve MASH indirectly through weight loss and improved insulin resistance, as the liver lacks direct GLP-1 receptors.

GLP-1 drugs like Semaglutide help MASH by making you lose weight and improving insulin sensitivity, not by acting directly on the liver. They are approved for obesity and diabetes and show strong benefits for liver health through these indirect pathways.

Metformin is effective for preventing type 2 diabetes in prediabetic women, with efficacy varying by menopausal stage and hormonal status.

If you are a woman with prediabetes, metformin is a proven tool to prevent type 2 diabetes, but its effectiveness depends heavily on your menopausal status. It works best for premenopausal women and those who have gone through natural menopause, rather than those who have had their ovaries removed. While lifestyle changes are the first step, metformin is particularly valuable for high-risk individuals (younger, higher BMI, history of gestational diabetes) where lifestyle changes alone may not be enough. Be prepared for potential gastrointestinal side effects, which often improve over time.

Phentermine-Topiramate produces moderate weight loss (7.87-8.45%) and improves cardiometabolic risk factors, but carries higher risks of neuropsychiatric and cardiovascular side effects compared to GLP-1RAs.

Phentermine-Topiramate is an oral medication that produces moderate weight loss (approx 8%). It is less effective than GLP-1RAs and carries higher risks of side effects like anxiety, paresthesia, and cardiovascular issues. It is not recommended for patients with existing heart disease.

GLP-1 receptor agonists reduce systolic blood pressure by 1.7 to 10.6 mmHg compared to placebo, contributing to stroke risk reduction.

GLP-1 drugs can help lower blood pressure, which is a key factor in preventing stroke. This effect is seen across different drugs in this class, with some showing reductions of up to 10 mmHg.

GLP-1 receptor agonists reduce the risk of atrial fibrillation by approximately 42% compared to placebo, which is a significant risk factor for stroke.

Taking GLP-1 drugs may also lower your risk of developing atrial fibrillation, a heart rhythm problem that increases stroke risk. This is another way these drugs protect your brain and heart.

Genetically proxied GLP-1R-based multi-target agonists (GIPR/GLP-1R, GCGR/GLP-1R, and GCGR/GIPR/GLP-1R) causally reduce the risk of Metabolic dysfunction-associated steatotic liver disease (MASLD) and its complications, including liver cancer and cardiovascular disease, partly independent of weight loss.

Genetic evidence strongly supports that GLP-1-based therapies (like semaglutide or tirzepatide) reduce the risk of fatty liver disease and its complications (liver cancer, heart disease). This benefit appears to come from improving metabolic health (insulin sensitivity, lipids) directly, not just from losing weight. If you have MASLD, these medications are a promising therapeutic option to discuss with your doctor, regardless of your current weight loss progress.

Discontinuation of semaglutide leads to significant weight regain ('semaglutide rebound'), with studies showing approximately two-thirds of lost weight is regained within one year.

If you stop taking semaglutide, expect to regain about two-thirds of the weight you lost within a year. This 'rebound' effect is common. Plan for sustainable lifestyle changes or discuss long-term management strategies with your doctor before stopping.

GLP-1 receptor agonists (semaglutide, tirzepatide) and dual agonists produce significant weight loss (15-22.5%) but are associated with lean muscle mass loss and require long-term adherence.

GLP-1 drugs like semaglutide and tirzepatide are highly effective for weight loss (15-22%), but you must take them long-term to maintain results. They can cause muscle loss, so combine them with resistance training and high protein intake. Be aware of GI side effects and contraindications like thyroid cancer history.

Performing bariatric surgery (Roux-en-Y or sleeve gastrectomy) prior to abdominoplasty significantly reduces postoperative complications and improves long-term stability compared to abdominoplasty alone in patients with metabolic syndrome.

If you have significant excess abdominal skin and metabolic issues (high blood pressure, diabetes, or high cholesterol), do not rush into skin removal surgery. You must first lose weight through diet, medication (like GLP-1s), or bariatric surgery until your weight and metabolic markers are stable for at least 6-12 months. This sequence drastically lowers your risk of infection, blood clots, and poor scarring, and ensures the skin removal looks good long-term.

Initiation of GLP-1 receptor agonists in adults with obesity or type 2 diabetes is associated with a substantially reduced risk of all-cause mortality, with the survival benefit being more pronounced in patients under 65 years of age and those with cardiometabolic comorbidities.

If you have obesity or type 2 diabetes, starting a GLP-1 RA (like semaglutide or liraglutide) is strongly associated with living longer, especially if you are under 65 or have other heart/kidney risks. While there is a small, early risk of pancreatitis, the survival benefit is substantial. Discuss this risk-benefit profile with your doctor, particularly if you have a history of pancreatic issues.

GLP-1 and GIP/GLP-1 receptor agonists (semaglutide, tirzepatide) cause a significant reduction in skeletal muscle mass (30-40% of total weight loss), posing a risk for sarcopenia, particularly in elderly patients and those with type 2 diabetes.

If you are taking semaglutide or tirzepatide, expect to lose some muscle along with fat. To protect your strength, you must eat more protein (at least 1.2g/kg/day) and perform resistance training 2-3 times per week. This is especially critical if you are older or already have low muscle mass.

GLP-1 receptor agonists lower blood pressure through central sympathetic inhibition, natriuresis, and improved endothelial function, with effects largely independent of weight loss.

GLP-1 drugs (like Ozempic or Wegovy) lower blood pressure through multiple pathways: they calm the nervous system's stress response, help kidneys excrete salt, and improve blood vessel health. This happens even before significant weight loss occurs.

MC4R agonists significantly reduce triglyceride and LDL-C levels, and lower systolic blood pressure, but have no significant effect on fasting blood sugar, HbA1c, or diastolic blood pressure.

MC4R agonists not only help you lose weight but also significantly improve your lipid profile by lowering triglycerides and LDL cholesterol, and they can lower systolic blood pressure. However, they do not appear to have a significant effect on fasting blood sugar, HbA1c, or diastolic blood pressure. These metabolic benefits make them a valuable treatment for reducing overall cardiovascular risk in patients with obesity.

Orforglipron 36 mg is the optimal dose for improving lipid profiles (triglycerides, total cholesterol) and blood pressure while maintaining better tolerability than 45 mg.

If your main goal is improving cholesterol and blood pressure rather than maximum weight loss, the 36 mg dose of orforglipron offers a good balance of efficacy and tolerability.

GLP-1 receptor agonists are associated with an increased risk of gallbladder and biliary tract diseases, particularly in obese individuals undergoing rapid weight loss, though the risk for pancreatitis is not consistently supported by recent large-scale data.

Be aware that GLP-1 medications slightly increase the risk of gallbladder issues, especially if you lose weight quickly. However, recent data suggests the risk of pancreatitis is not significantly higher than with other treatments. Discuss your personal risk factors with your doctor, who may recommend monitoring.

Early rapid weight loss (≥15% by Week 24) with incretin-based obesity medications (tirzepatide or semaglutide) predicts greater overall efficacy (higher probability of achieving ≥25-30% total weight loss) without negatively impacting study completion rates, despite a numerically higher incidence of gastrointestinal and hepatobiliary adverse events.

If you are starting tirzepatide or semaglutide, losing weight quickly in the first few months is a good sign that you will likely achieve your long-term weight loss goals. While you may experience more stomach issues early on, this does not mean you will quit treatment. Monitor your health, manage side effects as needed, and trust that early rapid response is a positive predictor of success.

Flexible, gradual titration of GLP-1 receptor agonists significantly reduces nausea and vomiting rates and discontinuation compared to standard rapid titration without compromising weight loss efficacy.

When starting a GLP-1 medication like semaglutide, do not rush to the highest dose. Start at the lowest possible dose and increase it slowly. If you feel mild nausea, pause the dose increase until it passes. If you vomit or feel significantly unwell, go back to the last dose that felt okay. This 'start low and go slow' approach prevents side effects and keeps you on the medication long enough to lose weight, which is the actual goal. You do not need to reach the maximum dose to get benefits; your body's tolerance is your guide.

Tirzepatide demonstrates superior weight reduction compared to Semaglutide 2.4 mg and significant MASH resolution in patients with histologically-proven MASH.

Tirzepatide is a once-weekly injection for diabetes and obesity that also shows strong promise for treating MASH. It reduces liver fat and inflammation significantly, with higher doses showing better results. It also leads to greater weight loss than Semaglutide in head-to-head comparisons.

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) induce weight loss by delaying gastric emptying and increasing satiety, but long-term cost-effectiveness modeling is hindered by uncertainty regarding sustained BMI trajectories and weight regain upon cessation.

GLP-1 medications like semaglutide and tirzepatide work by slowing digestion and reducing hunger, leading to significant weight loss. However, these drugs are not a one-time cure. Stopping treatment typically leads to weight regain, suggesting that obesity management with these agents is likely a long-term commitment. Cost-effectiveness models struggle to predict long-term outcomes because clinical trials are short, making it difficult to know if the weight loss will be sustained indefinitely.

SGLT2 inhibitors and GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) provide clinical benefits in obesity-related HFpEF, including symptom improvement and potential reverse cardiac remodeling, independent of or in addition to weight loss.

If you have obesity and heart failure with preserved ejection fraction, ask your doctor about SGLT2 inhibitors (like dapagliflozin) or GLP-1 agonists (like semaglutide). These drugs not only help with weight but also directly protect the heart by reducing inflammation and stiffness, improving symptoms and outcomes.